Cerenome Inc CNSY
News
Cerenome Secures National In-Network Agreement with Aetna for CNSide®
Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
Cerenome Launches CNSide® CSF Molecular Profile Tests
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Cerenome to Hold CNSide® Business Update Call on September 30, 2026
Trading Information
- Previous Close Price
- $0.67
- Day Range
- $0.60–0.65
- 52-Week Range
- $0.64–18.88
- Bid/Ask
- $0.63 / $0.65
- Shares Outstanding
- 7.59M
- Market Cap
- $5.01M
- Volume/Avg
- 13,287 / 604,751
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 28
- Website
- https://www.cerenome.com
Valuation
Metric | CNSY |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.90 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CNSY
Financial Strength
Metric | CNSY |
|---|---|
Quick Ratio | 1.23 |
Current Ratio | 1.37 |
Interest Coverage | −7.57 |
Quick Ratio
CNSY
Profitability
Metric | CNSY |
|---|---|
Return on Assets (Normalized) | −145.01% |
Return on Equity (Normalized) | −389.66% |
Return on Invested Capital (Normalized) | −325.00% |
Return on Assets
CNSY
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|%Nq#l@ | LOCK|c$F!b | $138B | |||
| Moderna Inc MRNA | LOCK|#ZpW&G | LOCK|>Mf | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|<Ml<@y | LOCK|BB$N^ | $93B | |||
| argenx SE ADR ARGX | LOCK|$!>bYz | LOCK|VXh | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|H^&?&r^ | LOCK|LS | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|KT&fVJgz | LOCK|xQBm% | $30B | |||
| Incyte Corp INCY | LOCK|P^v!@<? | LOCK|t>c | $24B | |||
| BioNTech SE ADR BNTX | LOCK|!wRdy% | LOCK|$Z | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|d$ft%@ | LOCK|>KQmb | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|#@!r$@ | LOCK|yz | $15B |
United States